ed for additional therapy, intubation, transfer to ICU, or death
• Secondary outcome includes reduction of IL-6 levels • Eicosapentaenoic acid free fatty acid (EPA-FFA) 1 g gastro-resistant capsules twice daily (2 g total) (NCT04335032, 2020)
• COLCORONA Trial
• Colchicine and inflam